Announced
Financials
Tags
Pending
Majority
Acquisition
Friendly
Single Bidder
United States
Private
Health Care Services
medical technology
Cross Border
Synopsis
Fresenius Kabi, an integrated pharmaceutical company, agreed to acquire Ivenix, a developer of an infusion management platform, for $240m. “Combining Ivenix’s expertise in pump technology and software with our infrastructure, portfolio, and presence in hospital settings represents an ideal opportunity. We intend to scale the launch of Ivenix’s next-generation infusion system while driving growth opportunities in the United States. With today’s announcement, Fresenius Kabi expects to create a leading, comprehensive infusion therapy offering,” Michael Sen, Fresenius Kabi President and CEO.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.